[43] also found that canagliflozin's antitumor activity is through SGLT2‐independent mechanisms, as canagliflozin's effects occurred in the absence of glucose and with knockdown of SGLT2 in breast cancer cells. The gene discussed is SLC5A2; the disease is breast cancer.